İsim: Etelcalcetide
CAS Numarası. : 1262780-97-1
Sekans: N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide disulfide with L-cysteine hydrochloride
Moleküler formül: C38H74ClN21O10S2
Molekül ağırlığı : 1084.71
Saflık: >98.0%
Kaynak: sentetik
Etelcalcetide kalsimimetik ve kalsiyum algılayan bir reseptördür (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. Bu paratiroid hormonunun sentezini ve salgılanmasını baskılar (PTH), böylece PTH seviyelerini düşürür ve serum kalsiyum ve fosfor seviyelerini düşürür. Yüksek PTH sıklıkla KBH hastalarında gözlenir ve düzensiz kalsiyum-fosfat homeostazisi ile ilişkilidir..
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
